Revolutionizing Biologics Regulation

Wechsler,Jill;

CONTINUE TO SITE

OR WAIT null SECS

Spotlight

COVID-19 Update Analytics Development Downstream Processing Manufacturing Outsourcing Quality/GMPs Upstream Processing

COVID-19 UpdateAnalyticsDevelopmentDownstream ProcessingManufacturingOutsourcingQuality/GMPsUpstream Processing

Topic

View More Analytical Methods BioBusiness Cell Culture/Fermentation Continuous Processing Drug Delivery Fill/Finish Formulation Process Chromatography Process Control/PAT Process Development QA/QC Separation and Purification Single-Use Systems Supply Chain

Analytical MethodsBioBusinessCell Culture/FermentationContinuous ProcessingDrug DeliveryFill/FinishFormulationProcess ChromatographyProcess Control/PATProcess DevelopmentQA/QCSeparation and PurificationSingle-Use SystemsSupply Chain

News

All News Top News Bio/Pharma News Industry News Supplier News Events

All NewsTop NewsBio/Pharma NewsIndustry NewsSupplier NewsEvents

Publications

All Publications BioPharm International

Resources

Podcast Series Biopharma Insights Sponsored eBooks Sponsored Podcasts Sponsored Videos Whitepapers

Podcast SeriesBiopharma InsightsSponsored eBooksSponsored PodcastsSponsored VideosWhitepapers

Webcasts

Enews Magazine

EnewsMagazine

About Us
Advertise
Editorial Information
Contact Us
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

Spotlight

COVID-19 Update
Analytics
Development
Downstream Processing
Manufacturing
Outsourcing
Quality/GMPs
Upstream Processing

TopicSee All >

Analytical Methods
BioBusiness
Cell Culture/Fermentation
Continuous Processing
Drug Delivery
Fill/Finish
Formulation
Process Chromatography
Process Control/PAT
Process Development
QA/QC
Separation and Purification
Single-Use Systems
Supply Chain

About Us
Advertise
Editorial Information
Contact Us
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

Revolutionizing Biologics Regulation

Published on: October 15, 2002

Jill Wechsler

BioPharm International, BioPharm International-10-01-2002, Volume 15, Issue 10

by Jill Wechsler

Related Content:

FDA Launches Major CGMP Review

Virus Inactivation in the 1990s ? and into the 21st Century: Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)

Process Validation: How Much to Do and When to Do It